Development of rational drug combinations with investigational targeted agents

Oncologist

Volumn 15, Issue 5, 2010, Pages 496-499

  Clark, Adam ^a   Ellis, Matthew ^b   Erlichman, Charles ^c   Lutzker, Stuart ^d   Zwiebel, James ^e  

^a Lance Armstrong Foundation   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d GENENTECH INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL RESEARCH; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; MONOTHERAPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG SYNERGISM; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952635663     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0262     Document Type: Article

References (2)

1. Engelman JA. The role of phosphoinosite-3-kinase pathway inhibitors in the treatment of lung cancers. Clin Cancer Res 2007;13:s4637-s4640.
2. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508